Sanofi makes another mRNA move with deal for skin microbiome biotech Origimm


Sanofi’s strategy to develop new messenger RNA vaccines is adding another piece. The pharmaceutical giant struck a deal to acquire Origimm Biotechnology, a startup developing therapeutic vaccines to treat skin diseases and infections.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.